Clinical Report: FDA Approves TECNIS PureSee IOL for Cataract Surgery
Overview
The FDA has approved the TECNIS PureSee intraocular lens (IOL), an extended depth of focus (EDOF) lens designed for cataract surgery. This lens aims to improve visual performance by addressing both cataract-related vision loss and presbyopia, while maintaining contrast sensitivity.
Background
Cataract surgery is a common procedure that can significantly enhance the quality of life for patients suffering from vision impairment. With an estimated 94 million individuals aged 50 and over experiencing moderate-to-severe distance vision issues, the introduction of advanced IOLs like the TECNIS PureSee is crucial. This lens not only addresses cataracts but also mitigates presbyopia, offering a broader range of vision.
Data Highlights
| Study | Findings |
|---|---|
| Pivotal Trial | All primary effectiveness endpoints met; PureSee improved intermediate visual acuity while maintaining distance acuity. |
| Contrast Sensitivity | Differences versus monofocal IOLs were ≤0.3 log units across spatial frequencies. |
| Adverse Events | No serious device-related adverse events; ocular serious events ≤4.8%. |
Key Findings
- TECNIS PureSee IOL is the first FDA-approved EDOF IOL with no warning on loss of contrast sensitivity.
- 97% of patients reported no very bothersome visual disturbances post-surgery.
- The lens provides excellent distance and intermediate vision, with some near vision capabilities.
- It uses a purely refractive OptiCurve posterior optic to extend depth of focus.
- FDA approval was based on a multicenter, randomized, bilateral, masked trial.
Clinical Implications
The introduction of the TECNIS PureSee IOL offers a new option for cataract patients, particularly those with presbyopia. Clinicians should consider this lens for patients seeking to reduce their dependence on glasses while maintaining visual clarity.
Conclusion
The FDA approval of the TECNIS PureSee IOL represents a significant advancement in cataract surgery, providing patients with enhanced visual performance and quality of life.
References
- Optometric Management, Optometric Management, 2026 -- Tecnis PureSee IOL Wins FDA Approval
- Ophthalmology Management, Ophthalmology Management, 2026 -- Tecnis PureSee IOL Wins FDA Approval
- Glaucoma Physician, Glaucoma Physician, 2026 -- FDA Approves Tecnis PureSee IOL
- Premarket Approval (PMA), FDA -- TECNIS PureSee IOL
- ESCRS, ESCRS Recommendations for Cataract Surgery
- the ophthalmologist — ASCRS 2026: New Data Highlight Performance of TECNIS PureSee EDOF IOL
- ASCRS 2026: New Data Highlight Performance of TECNIS PureSee EDOF IOL
- Premarket Approval (PMA)
- ESCRS - ESCRS Recommendations for Cataract Surgery
- Visual Performance Comparison Between Enhanced Monofocal and Extended Depth of Focus Intraocular Lenses: A Systematic Review and Meta-Analysis - PMC
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
